VIDAC Pharma Holding Plc
WKN: A3DTUQ | ISIN: GB00BM9XQ619 | SWB: T9G

Vidac Pharma is a clinical-stage biopharmaceutical company focused on developing first-in-class small-molecule drugs that target the altered metabolism of cancer and other serious diseases. By modulating specific metabolic checkpoints in diseased cells, Vidac aims to restore more normal cellular function and particularly Tumor micro environment (TME) making tumors more vulnerable to existing and future immunological and other
treatments.
By reversing, for the first time in drug design, the Warburg effect, the company reinstall apoptosis reversing also the “immortality” of tumor cells which are eliminated by normal “programmed death” mechanisms avoiding side effects. The company’s pipeline is centered on solid tumors and dermatological oncology indications, with the goal of offering new therapeutic options where current standards of care are often limited or unsatisfactory for patients.

Under the leadership of CEO Max Herzberg, Vidac Pharma brings together an experienced team with a long track record in drug development, life sciences entrepreneurship and value creation for investors. With its science-driven approach, focus on clearly defined patient populations and partnerships in key markets, the company seeks to translate its metabolic targeting concept into meaningful clinical benefit and long-term, sustainable growth.